Song Zhijun, Zhang John H
Department of Neurosurgery, Xingtai Third Hospital, Xingtai, China.
Department of Physiology, School of Medicine, Loma Linda University, Loma Linda, California.
Stem Cells Dev. 2020 Feb 15;29(4):178-186. doi: 10.1089/scd.2019.0219. Epub 2019 Dec 17.
Subarachnoid hemorrhage (SAH) is a type of hemorrhagic stroke with significant morbidity and mortality, and it often leads to poor clinical outcome. Although great efforts have been made toward animal and clinical studies, optimal therapy of SAH remains a challenge for scientists and clinicians. Increasing evidence suggests that stem-cell-based therapies may provide innovative approaches for treatment of SAH-related disability. In this review, we summarized the recent advances in stem cell research in SAH. Neuroregeneration after SAH could be conducted by the activation of endogenous neural stem cells (NSCs), transplantation of external stem cells, or reprogramming non-neuronal cell to neurons. The potential mechanism and signaling pathways, as well as the efficiency and safety of these stem cell treatments, were discussed in detail. Although lots of challenges remain for translating the laboratory findings and technologies into clinical therapies, these research studies provided the foundation and guidance for using different resources of stem cells as a brain repair strategy after SAH.
蛛网膜下腔出血（SAH）是一种具有显著发病率和死亡率的出血性中风，且常导致不良的临床结局。尽管在动物和临床研究方面已付出巨大努力，但SAH的最佳治疗方法对科学家和临床医生而言仍是一项挑战。越来越多的证据表明，基于干细胞的疗法可能为治疗SAH相关残疾提供创新方法。在本综述中，我们总结了SAH干细胞研究的最新进展。SAH后的神经再生可通过激活内源性神经干细胞（NSC）、移植外源性干细胞或使非神经元细胞重编程为神经元来实现。我们详细讨论了这些干细胞治疗的潜在机制和信号通路，以及其有效性和安全性。尽管将实验室研究结果和技术转化为临床治疗仍面临诸多挑战，但这些研究为将不同来源的干细胞用作SAH后脑修复策略提供了基础和指导。
